Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model

Cancer Gene Therapy

Volumn 17, Issue 10, 2010, Pages 742-750

  Lee, J M ^a   Yoon, S H ^a   Kim, H S ^a   Kim, S Y ^a   Sohn, H J ^a   Oh, S T ^b   Oh, I H ^a   Kim, T G ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

adoptive immunotherapy; chimeric immune receptor; interleukin 2; RNA electroporation; xenograft model

Indexed keywords

CELL RECEPTOR; CHIMERIC IMMUNE RECEPTOR; INTERLEUKIN 2; RNA; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; ELECTROPORATION; FEMALE; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; OVARY CANCER; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; DISEASE MODELS, ANIMAL; ELECTROPORATION; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, NATURAL KILLER CELL; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 77956884540     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.30     Document Type: Article

References (47)

1. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117: 1466-1476.
2. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002; 25: 15840-15842.
3. Cho HI, Hong YS, Lee MA, Kim EK, Yoon SH, Kim CC et al. Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas. Int J Hematol 2006; 83: 66-73.
4. Roskrow MA, Suzuki N, Gan Y, Sixbey JW, Ng CY, Kimbrough S et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkins disease. Blood 1998; 91: 2925-2934.
5. Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 2007; 13: 1440-1449.
6. Xue S, Gillmore R, Downs A, Tsallios A, Holler A, Gao L et al. Exploiting T cell receptor genes for cancer immunotherapy. Clin Exp Immunol 2005; 139: 167-172.
7. Gattinoni L, Powell Jr DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6: 383-393.
8. Birkholz K, Hombach A, Krug C, Reuter S, Kershaw M, Kämpgen E et al. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Therapy 2009; 16: 596-604.
9. Yoon SH, Lee JM, Cho HI, Kim EK, Kim HS, Park MY et al. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/ neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther 2009; 16: 489-497.
10. Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 2001; 248: 67-76.
11. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002; 169: 5780-5786.
12. Paulos CM,Wrzesinski C, Kaiser A, Hinrichs CS, ChieppaM, Cassard L et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 2007; 117: 2197-2204.
13. Ambade A, Mulherkar R. Adoptive T cell transfer augments IL-2 mediated tumour regression in a HNSCC xenograft nude mouse model. Cancer Lett 2008; 272: 316-324.
14. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988; 240: 1169-1176.
15. Dunne J, Lynch S, OFarrelly C, Todryk S, Hegarty JE, Feighery C et al. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol 2001; 167: 3129-3138.
16. Klingemann HG, Martinson J. Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy 2004; 6: 15-22.
17. Den Otter W, Jacobs JJ, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV et al. Local therapy of cancer with free IL-2. Cancer Immunol Immunother 2008; 57: 931-950.
18. Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, Eggermont AM et al. Immunotherapy of distant metastatic disease. Ann Oncol 2009; 20: 41-50.
19. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351: 2770-2771.
20. Heemskerk B, Liu K, Dudley ME, Johnson LA, Kaiser A, Downey S et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther 2008; 19: 496-510.
21. Jacobs JJ, Hordijk GJ, Jürgenliemk-Schulz IM, Terhaard CH, Koten JW, Battermann JJ et al. Treatment of stage IIIIV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2. Cancer Immunol Immunother 2005; 54: 792-798.
22. Maas RA, Van Weering DH, Dullens HF, Den Otter W. Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour. Cancer Immunol Immunother 1991; 33: 389-394.
23. Yoon SH, Lee JM, Woo SJ, Park MJ, Park JS, Kim HS et al. Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR). J Clin Immunol 29: 806-814.
24. Baum C, Kustikova O, Modlich U, Li Z, Fehse B. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther 2006; 17: 253-263.
25. Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine 2004; 28: 109-123.
26. Slos P, De Meyer M, Leroy P, Rousseau C, Acres B. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8+ T-cell immunity and NK activity. Cancer Gene Ther 2001; 8: 321-332.
27. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397-403.
28. Kim EJ, Cho D, Hwang SY, Kim TS. Interleukin-2 fusion protein with anti-CD3 single-chain Fv (sFv) selectively protects T cells from dexamethasone-induced apoptosis. Vaccine 2001; 20: 608-615.
29. Liu K, Rosenberg SA. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J Immunol 2001; 167: 6356-6365.
30. Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L et al. IL-2-induced activationinduced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci USA 2000; 97: 11445-11450.
31. Waldmann TA. The biology of interleukin-2 and interleukin- 15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6: 595-601.
32. Zambricki E, Shigeoka A, Kishimoto H, Sprent J, Burakoff S, Carpenter C et al. Signaling T-cell survival and death by IL-2 and IL-15. Am J Transplant 2005; 5: 2623-2631.
33. Hsu C, Hughes MS, Zheng Z, Bray RB, Rosenberg SA, Morgan RA. Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawalinduced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol 2005; 175: 7226-7234.
34. Rufer N, Migliaccio M, Antonchuk J, Humphries RK, Roosnek E, Lansdorp PM. Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood 2001; 98: 597-603.
35. Teng MW, Kershaw MH, Moeller M, Smyth MJ, Darcy PK. Immunotherapy of cancer using systemically delivered genemodified human T lymphocytes. Hum Gene Ther 2004; 15: 699-708.
36. Moeller M, Haynes NM, Kershaw MH, Jackson JT, Teng MW, Street SE et al. Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. Blood 2005; 106: 2995-3003.
37. Ferber D. Gene therapy: safer and virus-free? Science 2001; 294: 1638-1642.
38. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
39. Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 2006; 13: 1031-1049.
40. Breckpot K, Heirman C, Neyns B, Thielemans K. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. J Gene Med 2004; 6: 1175-1188.
41. Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother 2006; 55: 1432-1442.
42. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
43. Schaft N, Dö rrie J, Müller I, Beck V, Baumann S, Schunder T et al. A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes. Cancer Immunol Immunother 2006; 55: 1132-1141.
44. Zhao Y, Zheng Z, Cohen CJ, Gattinoni L, Palmer DC, Restifo NP et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther 2006; 13: 151-159.
45. Yu J, Wei M, Becknell B, Trotta R, Liu S, Boyd Z et al. Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity 2006; 24: 575-590.
46. Yui MA, Hernández-Hoyos G, Rothenberg EV. A new regulatory region of the IL-2 locus that confers positionindependent transgene expression. J Immunol 2001; 166: 1730-1739.
47. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 2009; 106: 3360-3365.